- The marvel of the cannabis plant is endless – here is an excerpt I came across this week speaking about the cannabis Sativa plant. The plant is a wonder of nature, a factory for brain-altering chemicals unlike any the world has ever seen. But there is a tremendous amount of variance between strains of the plant, with each grow resulting in a different balance of THC, CBD, and other elements. That leads to a robust market of products, but a hard one to regulate. Modern genomics might be the key to unlocking the plant’s ultimate potential. Several leading cannabis growers are engaged in efforts to sequence the Cannabis Sativa’s DNA, assembling a clear blueprint for how the plant generates the panoply of chemicals within. Reference
- CBD in Australia – Therapeutic Goods Administration is considering rescheduling CBD from a Schedule 4 to Schedule 3 drug. This would allow for the sale of pure CBD (with 2% or less other cannabinoids) to adults in packets containing up to 1,800mg of CBD. Such a change will reduce red tape around the accessibility of CBD products. Companies intending to sell CBD will need to adhere to strict production and quality measures. Patients will have a simpler means of accessing CBD, leading to competitive pricing as companies try to enter the market. To learn more about the changes, you can read the following. Link
Highlights of the Week:
- Brazil approves first medical cannabis product under 2019 regulations
- There is no difference between the effects of Indica and Sativa cannabis strains, scientists say
- Lebanon becomes the first Arab country to legalise cannabis for medical use
About Adam Isaac Miller:
Adam spent over 8 years building various B2B businesses within education, investment, and medicinal cannabis, with progressive roles including business development, strategy, product development, and project management. He has consulted private and listed cannabis producers and ancillary businesses since 2015, as one of the early entrants and experts in the burgeoning Australian cannabis industry. Adam founded and currently sits on the board of The Medical Cannabis Council, Australia’s largest not-for-profit industry body. He is a frequent public speaker and publishes a widely read industry newsletter. Adam earned a Bachelor of Entrepreneurship from the Royal Melbourne Institute of Technology.
Adam has appeared in several major news outlets including the Sydney Morning Herald, The Australian Financial Review, Startup Smart, SBS, SkyNews, MJBizDaily, and other major publications.